Drug Trial Radar · NCT05185622
A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
54
Actual
Start
Mar 21, 2022
Primary completion
Jul 16, 2024
Study completion Jul 16, 2024
Sponsor
- Lead sponsor
- Santhera PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II study is an open-label, multiple dose study to evaluate the safety, tolerability, PK, PD, clinical efficacy, behavior and neuropsychology, and physical functioning vamorolone over a treatment period of 12 weeks in steroid-naïve boys ages 2 to \<4 years, and glucocorticoid-treated and currently untreated boys ages 7 to \<18 years with DMD.
Conditions
- Duchenne Muscular Dystrophy
Interventions
VamoroloneDrug
Oral administration of vamorolone for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
- Number of Participants With Drug Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
- Number of Participants With Severe Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
- Number of Participants With Serious Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03)Time frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed (SAEs through 30 days after final dose of study drug)
- Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE v4.03) Leading to Study Treatment DiscontinuationTime frame: From the date of the subject's written informed consent until the final Week 16 Visit or the subject's participation in the study was completed
- Change in Height (Absolute) From Baseline to Week 12Time frame: Baseline, 12 weeks
- Change in Height (Percentile) From Baseline to Week 12Time frame: Baseline, 12 weeks
- Change in Height (Z-score) From Baseline to Week 12Time frame: Baseline, 12 weeks
- Change in Weight (Absolute) From Baseline to Week 12Time frame: Baseline, 12 weeks
- Change in Weight (Percentile) From Baseline to Week 12Time frame: Baseline, 12 weeks
- Change in Weight (Z-score) From Baseline to Week 12Time frame: Baseline, 12 weeks
- Change in Body Mass Index (BMI) (Absolute) From Baseline to Week 12Time frame: Baseline, Week 12
- Change in Body Mass Index (BMI) (Percentile) From Baseline to Week 12Time frame: Baseline, Week 12
- Change in Body Mass Index (BMI) (Z-score) From Baseline to Week 12Time frame: Baseline, Week 12
- Change in Diastolic Blood PressureTime frame: Day 1, Week 2, Week 6, Week 12, Week 16
- Change in Systolic Blood PressureTime frame: Day 1, Week 2, Week 6, Week 12, Week 16
- Number of Participants With Treatment Emergent Cushingoid FeaturesTime frame: Baseline through Week 16
- Number of Participants With Clinically Significant Treatment-emergent Abnormal Clinical Laboratory Test ResultTime frame: Day 1, Week 6, Week 12, Week 16
- Categorical Analysis of QTcF at Week 12Time frame: Baseline, Week 12
- Number of Eyes With CataractTime frame: Baseline - Week 12
- Number of Eyes With GlaucomaTime frame: Baseline - Week 12
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Montreal Childrens Hospital
Montreal, Canada
Alberta's Children Hospital
Calgary, Alberta, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.